Imperial College London
Portrait Picture

Dr James Kinross

Faculty of Medicine, Department of Surgery & Cancer

Reader in General Surgery
 
 
 
//

Contact

 

+44 (0)20 3312 1947j.kinross

 
 
//

Location

 

1029Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Harewood:2021:10.1007/s10552-021-01472-8,
author = {Harewood, R and Disney, R and Kinross, J and von, Wagner C and Cross, AJ},
doi = {10.1007/s10552-021-01472-8},
journal = {Cancer Causes and Control},
pages = {1047--1061},
title = {Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis},
url = {http://dx.doi.org/10.1007/s10552-021-01472-8},
volume = {32},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PurposeEvidence of differences in the etiology of, and poorer survival from, proximal colon compared to the distal colorectum, necessitates research into its risk factors. This systematic review summarizes the evidence on medication use and proximal colon cancer risk.MethodsMEDLINE and EMBASE were searched for prospective studies investigating nine medication groups, namely non-steroidal anti-inflammatory drugs (NSAIDs), exogenous hormones, i.e., hormone replacement therapy (HRT) or oral contraceptives (OCs), statins, proton pump inhibitors, anti-hypertensives, metformin (an antidiabetic), antidiarrheals or laxatives, and the risk of proximal colon cancer. Narrative synthesis and meta-analyses, using random effects models to estimate risk ratios (RRs) and 95% confidence intervals (CIs), were conducted.ResultsTwenty nine publications investigating NSAIDs (n = 13), exogenous hormones [HRT (n = 9) or OCs (n = 4)] statins (n = 5), anti-hypertensives (n = 1), and metformin (n = 1) were included. Summary RRs reported a protective effect of aspirin use (RR 0.80, 95% CI 0.73–0.89) but no associations between HRT (RR 0.92, 95% CI 0.83–1.02), OC (RR 1.06, 95% CI 0.98–1.14) or statin use (RR 0.94, 95% CI 0.67–1.31), and proximal colon cancer incidence compared to never/non-use. One study on metformin and one on anti-hypertensives reported no association. Sources of between-study heterogeneity included study design, period of exposure ascertainment, exposure source, and exposure comparison, but this exploration was hindered by the small numbers of studies.ConclusionDespite some studies on NSAID or HRT use, evidence on the impact of a range of medications on proximal colon cancer risk is limited. This highlights the need for more research to inform chemoprevention strategies.
AU  - Harewood,R
AU  - Disney,R
AU  - Kinross,J
AU  - von,Wagner C
AU  - Cross,AJ
DO  - 10.1007/s10552-021-01472-8
EP  - 1061
PY  - 2021///
SN  - 0957-5243
SP  - 1047
TI  - Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis
T2  - Cancer Causes and Control
UR  - http://dx.doi.org/10.1007/s10552-021-01472-8
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000669830400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://link.springer.com/article/10.1007%2Fs10552-021-01472-8
UR  - http://hdl.handle.net/10044/1/90430
VL  - 32
ER  -
Download